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The expression of peroxisome proliferator-activated receptor (PPAR)g in thyroid neoplasias and in normal thyroid (NT) tissues has
not been fully investigated. The objectives of the present work were: to study and compare the relative expression of PPARg in
normal, benign and malignant thyroid tissues and to correlate PPARg immunostaining with clinical/pathological features of patients
with thyroid cancer. We analysed the expression of PPARg in several types of thyroid tissues by reverse transcription–polymerase
chain reaction (RT–PCR), interphase fluorescent in situ hybridisation, real-time RT–PCR and immunohistochemistry. We have
demonstrated that NT tissues express PPARg both at mRNA and at protein level. PAX8-PPARg fusion gene expression was found in
25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10
normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas
(PDTCs). By real-time RT–PCR, we observed that tumours negative for the PAX8-PPARg rearrangement expressed lower levels of
PPARg mRNA than the NT. Overexpression of PPARg transcripts was detected in 80% (four of five) of translocation-positive
tumours. Diffuse nuclear staining was significantly (Po0.05) less prevalent in FTCs (53%; 18 of 34), PTCs (49%; 19 of 39) and PDTCs
(0%; zero of 13) than in normal tissue (77%; 36 of 47). Peroxisome proliferator-activated receptorg-negative FTCs were more likely
to be locally invasive, to persist after surgery, to metastasise and to have poorly differentiated areas. Papillary thyroid carcinomas with
a predominantly follicular pattern were more often PPARg negative than classic PTCs (80% vs 28%; P¼0.01). Our results
demonstrated that PPARg is underexpressed in translocation-negative thyroid tumours of follicular origin and that a further reduction
of PPARg expression is associated with dedifferentiation at later stages of tumour development and progression.
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Peroxisome proliferator-activated receptors (PPARs) are members
of the nuclear receptor superfamily, which form heterodimers with
retinoid X receptor. The heterodimers activate the transcription of
specific genes in response to binding of a ligand. Three PPAR
isoforms have been described: a, b (also called d, NUC-1 or FAAR)
and g (Desvergne and Wahli, 1999). PPARg is the most intensively
studied isoform. It has been shown that this nuclear receptor is
important in several biological pathways involving cell differentia-
tion, insulin sensitivity, atherosclerosis and cancer (Rosen and
Spiegelman, 2001). There are two protein isoforms (PPARg1 and
PPARg2) generated by alternative splicing and alternative promo-
ter usage. Peroxisome proliferator-activated receptorg1 isoform is
encoded by three transcripts, which differ in 50-untranslated region
(variants g1, g3 and g4). Variant g2 encodes isoform PPARg2
(Martin et al, 1998; Sundvold and Lien, 2001). Peroxisome
proliferator-activated receptorg2 contains 30 additional amino
acids in the N-terminus (Tontonoz et al, 1994). Peroxisome
proliferator-activated receptorg is activated by natural ligands
(fatty acids and eicosanoids) (Chawla and Lazar, 1994; Tontonoz
et al, 1994; Forman et al, 1995; Kliewer et al, 1995) and by synthetic
ligands (thiazolidinediones) (Lehmann et al, 1995). Peroxisome
proliferator-activated receptorg activation was reported to inhibit
the growth and, in some cases, to induce apoptosis or differentia-
tion of tumour cells from different lineages: liposarcoma
(Tontonoz et al, 1997; Demetri et al, 1999), breast cancer (Elstner
et al, 1998; Mueller et al, 1998), prostate cancer (Kubota et al,
1998), colorectal cancer (Brockman et al, 1998; Sarraf et al, 1998;
Kitamura et al, 1999), bladder cancer (Guan et al, 1999), non-
small-cell lung carcinoma (Chang and Szabo, 2000), pancreatic
cancer (Motomura et al, 2000), gastric cancer (Sato et al, 2000),
renal carcinoma (Inoue et al, 2001), testicular cancer (Hase et al,
2002) and liver cancer (Toyoda et al, 2002).
Kroll et al (2000) reported that t(2;3)(q13;p25), a chromosomal
translocation detected in a subset of follicular thyroid carcinomas
(FTCs), originates a fusion gene composed by DNA-binding
domain of the thyroid transcription factor PAX8 and domains A to
F of PPARg. Recently, our group and others (Marques et al, 2002;
Nikiforova et al, 2002; Cheung et al, 2003) have detected the
expression of PAX8-PPARg gene not only in FTCs but also in
follicular thyroid adenomas (FTAs). Ohta et al (2001) studied the
expression of PPARg in papillary thyroid carcinoma (PTC) cell
lines and in thyroid tumours. They showed that most cell lines and
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yhalf of PTCs expressed PPARg, while normal adjacent tissue and
two FTAs were negative. This group as well as Martelli et al (2002)
also demonstrated that PPARg agonists induce apoptosis and
inhibit the growth of thyroid tumour cells.
Several studies have demonstrated that, compared to their
normal counterparts, the expression of PPARg in tumour cells is
either overexpressed, such as in renal cell carcinoma (Inoue et al,
2001) and testicular cancer (Hase et al, 2002), underexpressed,
such as in oesophageal carcinomas (Terashita et al, 2002) or is
equal to the normal tissue, such as in colonic adenocarcinomas
(Sarraf et al, 1998). This last group has also identified somatic
mutations of PPARg in four of 55 sporadic primary colorectal
carcinomas (Sarraf et al, 1999). The expression of PPARg in
thyroid neoplasias and in the normal thyroid (NT) tissue has not
been fully investigated. We have expanded our previous study
(Marques et al, 2002) and analysed the expression of PPARg in a
series of thyroid tumours and correspondent normal tissue by
reverse transcription–polymerase chain reaction (RT–PCR),
interphase fluorescent in situ hybridisation (FISH), real-time
RT–PCR and immunohistochemistry. We observed that PPARg
expression is usually underexpressed in multiple types of thyroid
tumours, and that this may be an important event in the
development of thyroid neoplasias.
MATERIALS AND METHODS
Materials
The number of cases analysed by each technique for the different
histological groups is represented in Table 1. Paraffin-embedded
tissues and frozen tissues were available in 247 samples and in 131
samples, respectively. Haematoxylin- and eosin-stained sections
from each sample were evaluated histologically by two pathologists
to classify tumours according to the 1988 World Health Organisa-
tion histological classification of thyroid tumours. The extent of
papillary carcinomas was classified according to the system of
DeGroot et al (1990) and the metastasis-age-completeness-of-
resection-invasion-size-score (MACIS) (Hay et al, 1993). The
system of DeGroot et al (1990) categorises the patients with PTC
by clinical class: I, with intrathyroidal disease; II, with cervical
adenopathies; III, with extrathyroidal invasion and IV, with distant
metastasis. The prognostic score defined as MACIS was calculated
according to Hay et al (1993): MACIS¼3.1 (if aged p39 years) or
0.08 age (if aged X40 years), þ0.3 tumour size (in centi-
metres), þ1 (if incompletely resected), þ1 (if locally invasive)
and þ3 (if distant metastasis present).
RNA extraction, RT–PCR and sequencing
Total RNA was extracted from frozen tumours using TRIzol
reagent (Life Technologies, Inc., Gaithersburg, MD, USA), accord-
ing to the manufacturer’s protocol. RNA was quantified by UV
spectrophotometry (optical density measured at 260nm). Com-
plementary DNA (cDNA) was synthesised from 1mg of RNA at
371C for 90min, using oligo-(dT) primers (Life Technologies, Inc.)
and reverse transcriptase (Life Technologies, Inc.). PAX8-PPARg
fusion gene expression was analysed by RT–PCR as described
previously (Marques et al, 2002).
To analyse the expression of the various PPARg mRNA
isoforms, segments from the 50-terminal region of the PPARg
gene were amplified by PCR using forward primers, located in
exons A1,A 2 and B and reverse primers located in exon 1. Primer
sequences are presented in Table 2. First round amplifications
were performed using 1ml of cDNA, forward primers P1,P 3 and P5
and reverse primer P7. A measure of 1ml of each amplification
reaction was then used as template for second amplification
reactions with nested primers P2,P 4,P 6 (forward) and P8 (reverse).
A total of 25ml reactions were carried out on over 35 cycles using
the following conditions: 951C for 1min, 55–571C for 1min and
721C for 1min. Amplification reactions contained final concentra-
tions of 20mM Tris-HCl (pH 8.4), 50mM KCl, 200mM dNTPs
(Amersham Pharmacia Biotech, Uppsala, Sweden), 1.0–2.5mM
MgCl2, 10pmol of each primer (forward and reverse) and 1.5U of
Taq DNA Polymerase (Life Technologies, Inc.). Negative controls
for cDNA synthesis and PCRs, in which the template was replaced
by sterile water, were included in each experiment. RNA integrity
and efficiency of cDNA synthesis were tested in each sample by
performing RT–PCR amplification for the housekeeping gene
phosphoglycerate kinase-1 (Sugg et al, 1998). Normal colon tissue
was used as positive control for the analysis of PPARg expression
(Sarraf et al, 1998).
PCR products were analysed and purified by electrophoresis in a
2% agarose gel stained with ethidium bromide. Polymerase chain
reaction products were also subjected to automatic sequencing
(ABI Prism 310 Genetic Analyser using the ABI Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit Version 2;
Applied Biosystems, PE Corporation, Foster City, CA, USA).
Interphase FISH analysis
Fluorescent in situ hybridisation was performed on isolated nuclei
extracted from 50mm paraffin-embedded sections of thyroid
tumours with BAC probes for PPARg (RPCI 1130 G23, BAC PAC
Resources) and PAX8 (RPCI 1165 I12, BAC PAC Resources).
Briefly, PPARg clone DNA was labelled with digoxigenin and PAX8
DNA with biotin by random priming, using the Bioprime DNA
labelling system (Invitrogen S.A., Barcelona, Spain). Nuclear
suspensions were spotted on SuperFrost slides (Menzel-Glaser,
GMbH, Memmert, Germany) and pretreated with 0.1% pepsin
(Sigma-Aldrich, St Louis, MO, USA) in 0.2% HCl at 371C. Probe
mixture in 50% formamide in 2 SSC was codenatured with
nuclear DNA at 801C for 2min. Detection of the digoxigenin-
labelled PPARg probe was accomplished using an anti-digoxigenin
Table 1 Thyroid tissues analysed for PPARg expression
Techniques
Histology RT–PCR/FISH
Real-time
RT–PCR
PPARc
staining
Normal thyroid 10 10 47
Nodular hyperplasia 28 0 28
Follicular adenomas 36 13 86
Follicular carcinomas 24 7 34
Papillary carcinomas 38 9 39
Poorly differentiated
carcinomas
11 0 13
RT–PCR¼reverse transcription–polymerase chain reaction; FISH¼fluorescent in
situ hybridisation; PPAR¼peroxisome proliferator-activated receptor.
Table 2 RT–PCR oligonucleotide primer sequences
Primer Exon (PPARc) Sequence (50–30)
P1 (forward) A1 CGGAGCCCGAGCCCGAG
P2 (forward) A1 CAGCCGCCGCCTGGGGC
P3 (forward) A2 ACACTAAACCACCAATATACAA
P4 (forward) A2 CAAGGCCATTTTGTCAAACG
P5 (forward) B CGGATTGATCTTTTGCTAGAT
P6 (forward) B GTTATGGGTGAAACTCTGGG
P7 (reverse) 1 CAAAGGAGTGGGAGTGGTCT
a
P8 (reverse) 1 CATTACGGAGAGATCCACGGT
a
RT–PCR¼reverse transcription–polymerase chain reaction; PPAR¼peroxisome
proliferator-activated receptor.
aKroll et al (2000).
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yfluorescein antibody (Roche Diagnostics GMbH, Manheim,
Germany) and the biotinylated-labelled PAX8 probe with CY3–
avidin (Jackson Immunoresearch Lab, West Grove, USA). Nuclei
were counterstained with DAPI-Vectashield mounting solution
(Vector, Burlingame, USA). Fluorescence hybridisation signals
were analysed and recorded with a Cytovision System (Applied
Imaging, New Castle, UK). For each case 200 intact nonoverlap-
ping nuclei were counted. Nuclei in which the two probes were
fused, touched or were close to each other (distance p1 probe
signal) were scored as positive for the fusion gene.
Real-time RT–PCR
The real-time quantitative PCR was performed in a 96-well
reaction plate (MicroAmp
sOptical 96-Well Reaction Plate, Ap-
plied Biosystems, PE Corp.) on an ABI PRISM
s 7000 Sequence
Detector System (Applied Biosystems, PE Corp.), according to the
manufacturer’s instructions. TaqMan
s One Step PCR Master Mix
Reagents Kit (P/N 4309169; Applied Biosystems, PE Corp.) was
used to generate fluorescence signals during each PCR cycle.
Specific primers and the probe were designed by Pre-Developed
Taqman
sAssay Reagents (Assays-on-demand, P/N 4331182, Ap-
plied Biosystems, PE Corp.). The amplified region contained exons
5 and 6 from PPARg gene. In order to normalise the differences in
the amount of total RNA used in each reaction, we performed the
amplification of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) RNA as endogenous control (FG HUMAN GAPDH
0211014, P/N 4333764F, Applied Biosystems, PE Corp.). A pool of
five NT tissues was used as calibrator for determining the relative
expression of PPARg gene in the tumour samples as described
previously (Lazar et al, 1999).
Immunohistochemistry
Formalin-fixed paraffin-embedded sections (3mm) were attached
to glass slides pretreated with gelatin. The sections were then dried
at 371C overnight and dewaxed with xylol. Endogenous peroxidase
was inhibited with 0.6% H2O2 in methanol for 10min. Antigen
retrieval was performed using a stainless-steel 6-l capacity pressure
cooker, with 0.01 M sodium citrate buffer (pH 6.0), for 6min at full
pressure. Slides were incubated with normal goat serum 1:10
(DAKO X907, DAKO Corp., Golstrup, Denmark) for 10min before
blocking the endogenous avidin and biotin (Vector SP-2001,
Vector Laboratories, Inc., Burlingame, CA, USA). Peroxisome
proliferator-activated receptorg primary antibody 1:30 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was incubated for
30min. Specificity of PPARg immunostaining was demonstrated
by preincubating the samples with PPARg blocking peptide 1:10
(Santa Cruz Biotechnology, Inc.). Bound primary antibody was
detected using biotinylated goat anti-mouse and anti-rabbit
immunoglobulin G, being subsequently amplified with streptavi-
din conjugated to horseradish peroxidase (DAKO K5001; DAKO
Corp.). All incubations were performed at room temperature. The
peroxidase staining reaction was revealed with a solution contain-
ing 3,30-diaminobenzidine tetrachloride. Sections were counter-
stained with Mayer’s haematoxylin, dehydrated and mounted.
Statistical analysis
The frequencies of PPARg transcript variants and the level of
PPARg mRNA in each tumour histotype were analysed by w
2 test
and unpaired t-test, respectively. Peroxisome proliferator-acti-
vated receptorg mRNA levels in PTCs and in corresponding NT
tissues were compared using a paired t-test. Peroxisome pro-
liferator-activated receptorg immunostaining for nodular hyper-
plasias (NH) and thyroid tumours was compared with the staining
in NT tissues by two-tailed Fisher’s exact test. We also correlated
the PPARg immunostaining in FTCs and PTCs with clinical/
pathological features of the patients by unpaired t-test, two-tailed
Fisher’s exact test or w
2 test as appropriate. P-values less than 0.05
were considered significant. Statistical analysis was performed
using Graph Pad Prism version 2.0 (San Diego, CA, USA).
RESULTS
Analysis of PPARc transcript variants
RNA from 72 frozen samples (6 normal tissues, 29 FTAs, 9 FTCs,
24 PTCs and four poorly differentiated thyroid carcinomas
(PDTCs)) was analysed by RT–PCR. Peroxisome proliferator-
activated receptorg transcript variants were determined by
combining the RT–PCR results obtained for each primer pair.
Peroxisome proliferator-activated receptorg3 could be detected
only in the five cases that did not present PPARg1, because RT–
PCR with primer pairs P3P7 or P4P8 originated products with
exactly the same size in both variants. Most thyroid tissues
expressed PPARg1, PPARg2 and PPARg4, and the proportion of
specific variants expressed was similar in NT tissues and in the
various types of thyroid tumours (data not shown).
PAX8-PPARc fusion gene expression
The fusion gene was detected by RT–PCR and/or interphase FISH
analysis. Six out of 24 (25%) FTCs and six out of 36 (17%) FTAs
were positive for PAX8-PPARg fusion gene expression. The
rearrangement was not detected in 10 NT tissues, 28 NHs, 38
PTCs and 11 PDTCs.
Quantitative analysis of PPARc gene expression
The mRNA level of PPARg in thyroid tissues is represented in
Figure 1. The mean expression level in PAX8-PPARg-negative
FTAs (0.1470.22; P¼0.001) and FTCs (0.2270.23; P¼0.05) was
significantly lower than in normal tissue (0.6870.40). In contrast,
PAX8-PPARg-positive FTAs and FTCs presented mean PPARg
mRNA levels, which were, respectively, 22- (14.6870.67;
Po0.0001) and 17-fold (11.88710.09; P¼0.002), higher than the
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Figure 1 Quantitative analysis of PPARg expression by real-time RT–
PCR in several thyroid samples. The mean expression in negative PAX8-
PPARg follicular tumours (FTA: 0.1470.22; P¼0.001 and FTC:
0.2270.23; P¼0.05) and in papillary carcinomas (0.1870.10; P¼0.002)
was lower than in NT tissue (0.6870.40). PAX8-PPARg-positive follicular
adenomas and carcinomas presented PPARg mRNA levels that were
increased by 22- (14.6870.67; Po0.0001) and 17-fold (11.88710.09;
P¼0.002) compared to normal tissue (0.6870.40). One FTC case positive
for the fusion gene exhibited a PPARg mRNA level (0.84) within the
normal mean. FTC – follicular thyroid carcinomas; FTA – follicular thyroid
adenomas; PTC – papillary thyroid carcinomas, NT – normal tissue.
PPARc expression in thyroid tissues
AR Marques et al
734
British Journal of Cancer (2004) 91(4), 732–738 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ynormal mean. However, one FTC case positive for the fusion gene
showed a ratio (0.84) within the normal mean (0.6870.40). We
also observed that PTCs showed a ratio (0.1870.10; P¼0.002)
lower than in the NT. This is clearly demonstrated in Figure 2,
where paired comparison of PPARg expression between tumours
and normal adjacent tissues from the same patients showed a
significant decrease of PPARg expression in PTCs (0.1770.09 vs
0.4870.34; P¼0.02).
PPARc immunohistochemistry
Table 3 presents the intensities of PPARg nuclear immunostaining
for each tumour histotype. Representative results are shown in
Figure 3. Diffuse nuclear immunoreactivity, usually faint or
moderate, was detected in 77% (36 of 47) of NT tissues, 53% (18
of 34) of FTCs (P¼0.03 vs normal tissue), 49% (19 of 39) of PTCs
(P¼0.01 vs normal tissue), 62% (53 of 86) of FTAs (P¼0.09 vs
normal tissue) and in 71% (20 of 28) of NHs (P¼0.78 vs normal
tissue). All PDTCs (n¼13) were negative (Po0.0001 vs normal
tissue). All translocation-positive FTAs (n¼6) and five of six FTCs
showed PPARg staining usually moderate or strong in intensity.
Tumour staining was similar to the intensity in the normal
adjacent tissue in 62% (29 of 47) of cases, was lower in 28% (13 of
47) of cases and stronger in 10% (five of 47) of cases. Frozen tissue
was available in two out of the five cases staining stronger than the
normal tissue; PAX8-PPARg fusion gene was present in these two
cases.
Correlation between PPARc immunohistochemistry and
clinical/pathological data
Clinical and pathological features of malignant tumours are
presented in Tables 4 and 5. When statistical analysis was
performed between PPARg-positive and -negative tumours, we
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Figure 2 Quantitative analysis of PPARg mRNA by real-time RT–PCR
in thyroid tumours and in the corresponding normal adjacent tissue. The
expression level in each PTC was lower than in normal adjacent tissue. The
PPARg mRNA level in two FTAs was also lower than in corresponding
normal tissues. One FTC translocation-positive exhibited a ratio similar to
its surrounding normal tissue. PTC – papillary thyroid carcinoma; FTA –
follicular thyroid adenoma; FTC – follicular thyroid carcinoma; NT – normal
thyroid.
Table 3 PPARg immunohistochemistry in thyroid tumours
PPARc immunostaining
Tissue Negative Positive P-value
NT (n¼47) 11 (23%) 36 (77%)
NH (n¼28) 8 (29%) 20 (71%) NS
FTA (n¼86) 33 (38%) 53 (62%) NS
FTC (n¼34) 16 (47%) 18 (53%) 0.03
PTC (n¼39) 20 (51%) 19 (49%) 0.01
PDTC (n¼13) 13 (100%) 0 o0.0001
NS¼not significant; NT¼normal thyroid; NH¼nodular hyperplasia; FTA¼folli-
follicular thyroid adenoma; FTC¼follicular thyroid carcinoma; PTC¼papillary
thyroid carcinoma; PDTC¼poorly differentiated thyroid carcinoma; PPAR¼peroxi-
peroxisome proliferator-activated receptor.
Figure 3 PPARg protein expression in thyroid tissues assessed by immunohistochemistry. Positive cases presented diffuse nuclear immunostaining. (A)
Negative poorly differentiated carcinoma; (B) papillary carcinoma of classic variant with faint immunostaining and corresponding peritumoral (C) and
contralateral (D) normal tissue, both with moderate immunoreativity. (A–D) original magnification  400.
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yobserved that 86% (six of seven) of FTCs with distant metastasis
were PPARg negative (P¼0.03). There was also a trend for
negative tumours to be more locally invasive (75%), to have poorly
differentiated areas (71%) and to have persistent disease after
surgery (80%). Most (75%) of the widely invasive FTCs were
PPARg negative, whereas only 38% of minimally invasive tumours
did not shown PPARg staining. The two widely invasive tumours
positive for PPARg had two different components: a follicular area,
which stained positive, and an insular area, which was negative.
Positive PPARg staining was not correlated with age, gender,
tumour size or vascular invasion. In PTC cases, we observed that
72% (13 of 18) of the tumours with a classic pattern were positive,
whereas 80% (12 of 15) of the follicular variants were negative
(P¼0.01). Peroxisome proliferator-activated receptorg staining
did not correlate with any other prognostic variable but,
interestingly, all class IV tumours (n¼3) were negative.
DISCUSSION
We (Marques et al, 2002) and others (Kroll et al, 2000; Nikiforova
et al, 2002; Aldred et al, 2003; Cheung et al, 2003) have detected
cases of thyroid tumours, such as FTC, FTA or PTC, that exhibit
mild or moderate diffuse PPARg nuclear staining, even though
they are RT–PCR negative for the PAX8-PPARg fusion gene. The
question was then whether such cases present or not over-
expression of PPARg. It is important to discriminate between these
two possibilities, because underlying different pathogenic mechan-
isms may be present. For instance, if PPARg expression is found to
be upregulated in PAX8-PPARg-negative tumours, it could reflect
either a breakpoint between PAX8 and PPARg in a location outside
the primers used in the RT–PCR reaction, or a rearrangement
between PPARg and a non-PAX8 partner, or overexpression of
wild-type PPARg or point mutations in the PPARg gene. The
objectives of the present work were two-fold: 1 – to study, and
compare, the relative expression of PPARg in the normal gland and
in benign and malignant diseases of the thyroid; and 2 – to
correlate PPARg immunostaining with clinical and pathological
characteristics of patients with thyroid carcinomas of follicular
origin. We chose to examine PPARg expression in thyroid tissues
by RT–PCR, interphase FISH, real-time RT–PCR and immuno-
histochemistry. We first demonstrated that NT tissues express
PPARg both at mRNA and at the protein level. This is in contrast
with the findings by Ohta et al (2001), who detected PPARg mRNA
in four of six PTC cell lines and in three of six PTCs, but not in NT
tissues or in FTAs. However, our results are in concordance with
the recent data of Aldred et al (2003), who have also demonstrated
PPARg expression in seven of seven NT specimens. Interestingly,
the mean ratio of PPARg/GAPDH mRNA obtained by the
semiquantitative method of Aldred et al (2003) of 0.7970.30 is
not far from the ratio of 0.6870.40 obtained by our quantitative
method. As the human PPARg gene gives rise to four mRNAs,
PPARg1–4, that differ at their 50-end as a consequence of alternate
promoter usage and splicing, and these mRNAs code two protein
isoforms, PPARg1 and PPARg2, which may exert distinct biological
effects, we investigated the expression of the different PPARg
transcripts in the thyroid tissues. We were able to show that
thyroid cells express all mRNA isoforms, but the proportion of
specific variants was similar in normal tissues and in the various
types of thyroid tumours studied. However, because we did not
perform quantitative RT–PCR, it is possible that some tumour
types predominantly express one of the isoforms. To compare
PPARg expression between tumours and NT tissues, we performed
quantitative analysis by real-time RT–PCR. Our assay did not
distinguish wild-type transcripts from PAX8-PPARg fusion
mRNAs. We observed that tumours negative for the rearrangement
expressed lower levels of PPARg mRNA than NT. This was
particularly evident in the PTC cases (n¼7) in which the normal
adjacent tissue of the same patient was also available for analysis
(Figure 2). Upregulation of PPARg mRNA levels was found in four
of the five (80%) translocation-positive tumours (three FTC and
two FTA) analysed. However, we detected one PAX8-PPARg-
positive case (FTC) with a PPARg/GAPDH ratio within the mean of
the normal group. Interphase FISH analysis revealed that only a
small subset of cells in this case harboured the translocation, which
is consistent with the normal expression level of PPARg as assessed
by real-time RT–PCR. Overall, there was a direct correlation
between our real-time analysis of PPARg expression and the
immunoreactive protein: strong immunostaining was present only
in tumours with upregulated PPARg mRNA levels and mild or
moderate staining was revealed in the remaining tumours, as well
Table 4 Clinical and pathological features and PPARg expression in
follicular carcinomas
PPARc immunohistochemistry
FTC
All
(n¼34)
Negative
(n¼16)
Positive
(n¼18) P-value
Age at diagnosis (years7s.d.) 55.6716.8 59.4715.7 52.2717.5 NS
F/M ratio 2.4/1 4.3/1 1.6/1 NS
Tumour size (cm7s.d.) 4.171.9 3.871.6 4.472.2 NS
Invasiveness NS
Minimally invasive 26 10 (38%) 16 (62%)
Widely invasive 8 6 (75%) 2 (25%)
Poorly differentiated areas 7 5 (71%) 2 (29%) NS
Local invasion 4 3 (75%) 1 (25%) NS
Vascular invasion 24 13 (54%) 11 (46%) NS
Distant metastasis 7 6 (86%) 1 (14%) 0.03
Clinical status
a NS
Persistent 5 4 (80%) 1 (20%)
Remission 28 12 (43%) 16 (57%)
Nonthyroid neoplasias 3 1 (33%) 2 (67%) NS
PPAR¼peroxisome proliferator-activated receptor; s.d.¼standard deviation;
NS¼not significant.
aLoss of follow-up of one patient.
Table 5 Clinical and pathological features and PPARg expression in
papillary carcinomas
PPARc immunohistochemistry
PTC
All
(n¼39)
Negative
(n¼20)
Positive
(n¼19) P-value
Age at diagnosis (years7s.d.) 41.0719.9 38.7718.7 43.5721.3 NS
F/M ratio 2.5/1 1.9/1 3.4/1 NS
Tumour size (cm7s.d.) 3.772.4 3.972.1 3.572.3 NS
MACIS (mean7s.d.) 5.571.8 5.672.0 5.571.7 NS
Class
a NS
I 20 11 (55%) 9 (45%)
II 6 3 (50%) 3 (50%)
III 9 2 (22%) 7 (78%)
IV 3 3 (100%) 0
Predominant pattern 0.01
Classic 18 5 (28%) 13 (72%)
Follicular 15 12 (80%) 3 (20%)
Others 6 3 (50%) 3(50%)
Poorly differentiated areas 6 4 (67%) 2 (33%) NS
Local invasion 13 6 (46%) 7 (54%) NS
Vascular invasion 9 4 (44%) 5 (56%) NS
Clinical status
a NS
Persistent 9 3 (33%) 6 (67%)
Remission 29 16 (55%) 13 (45%)
PPAR¼peroxisome proliferator-activated receptor; PTC¼papillary thyroid carci-
noma; s.d.¼standard deviation; NS¼not significant.
aLoss of follow-up of one
patient.
PPARc expression in thyroid tissues
AR Marques et al
736
British Journal of Cancer (2004) 91(4), 732–738 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yas in normal tissues. Notably, the translocation-positive FTC with
normal PPARg/GAPDH ratio showed diffuse and faint nuclear
staining. Aldred et al (2003) performed semiquantitative RT–PCR
analysis of PPARg expression in 14 NT tissues and in 19 FTCs and
also showed that nontranslocation tumours had underexpression
of PPARg.
A larger number of tissues were examined by immunohisto-
chemistry in order to determine, and compare, the prevalence of
PPARg staining between normal, hyperplastic and neoplastic
tissues, and to correlate staining with known prognostic variables
of thyroid carcinomas. Compared to NT tissues, staining was
significantly (Po0.05) less prevalent in FTCs, PTCs and PDTCs.
This trend was also present in FTAs, although not statistically
significant (P¼0.09). Previous studies have shown that FTCs
harbouring the fusion gene, hence strongly reactive with a PPARg
antibody, are somewhat smaller in size (Cheung et al, 2003;
Nikiforova et al, 2003), more overtly invasive, and occur at a
younger age than tumours without the rearrangement (Nikiforova
et al, 2003). In the study of French et al (2003), FTCs with PPARg
rearrangement had vascular invasion and a solid/nested histology
more frequently than translocation-negative tumours. We ob-
served that PPARg-negative FTCs were more likely to be locally
invasive, to persist after surgery, to metastasise and to have poorly
differentiated areas.
We could not correlate PPARg staining with any of the
prognostic variables analysed in the group of PTCs, except for
tumours presenting a predominantly follicular pattern that were
more often negative (80%) than classic PTCs (28%; P¼0.01).
In summary, we have demonstrated underexpression of PPARg
in PAX8/PPARg-negative thyroid tumours of follicular origin, and
that a further reduction of PPARg expression is associated with
dedifferentiation at later stages of tumour development.
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